TY - JOUR
KW - primary care
KW - opioid use disorder
KW - rural
AU - E. S. Cole
AU - E. DiDomenico
AU - S. Green
AU - S. K. R. Heil
AU - T. Hilliard
AU - S. E. Mossburg
AU - A. L. Sussman
AU - J. Warwick
AU - J. M. Westfall
AU - L. Zittleman
AU - J. G. Salvador
A1 - 
AB - Access to treatment for opioid use disorder (OUD) in rural areas within the United States remains a challenge. Providers must complete 8-24 h of training to obtain the Drug Addiction Treatment Act (DATA) 2000 waiver to have the legal authority to prescribe buprenorphine for OUD. Over the last 4 years, we executed five dissemination and implementation grants funded by the Agency for Healthcare Research and Quality to study and address barriers to providing Medications for Opioid Use Disorder Treatment (MOUD), including psychosocial supports, in rural primary care practices in different states. We found that obtaining the DATA 2000 waiver is just one component of meaningful treatment using MOUD, and that the waiver provides a one-time benchmark that often does not address other significant barriers that providers face daily. In this commentary, we summarize our initiatives and the common lessons learned across our grants and offer recommendations on how primary care providers can be better supported to expand access to MOUD in rural America.
AD - Graduate School of Public Health, Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA, USA.; The Pennsylvania Department of Drug and Alcohol Programs, Harrisburg, PA, USA.; Gillings School of Global Public Health, Department of Maternal and Child Health, University of North Carolina - Chapel Hill, Chapel Hill, NC, USA.; American Institutes for Research, Washington, DC, USA.; American Institutes for Research, Washington, DC, USA.; American Institutes for Research, Washington, DC, USA.; Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USA.; Program Evaluation and Research Unit, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.; Department of Family Medicine, University of Colorado, Aurora, CO, USA.; Department of Family Medicine, University of Colorado, Aurora, CO, USA.; Department of Psychiatry and Behavioral Sciences, University of New Mexico, Albuquerque, NM, USA.
BT - Substance abuse
C5 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
CY - United States
DO - 10.1080/08897077.2021.1891492
JF - Substance abuse
LA - eng
M1 - Journal Article
N2 - Access to treatment for opioid use disorder (OUD) in rural areas within the United States remains a challenge. Providers must complete 8-24 h of training to obtain the Drug Addiction Treatment Act (DATA) 2000 waiver to have the legal authority to prescribe buprenorphine for OUD. Over the last 4 years, we executed five dissemination and implementation grants funded by the Agency for Healthcare Research and Quality to study and address barriers to providing Medications for Opioid Use Disorder Treatment (MOUD), including psychosocial supports, in rural primary care practices in different states. We found that obtaining the DATA 2000 waiver is just one component of meaningful treatment using MOUD, and that the waiver provides a one-time benchmark that often does not address other significant barriers that providers face daily. In this commentary, we summarize our initiatives and the common lessons learned across our grants and offer recommendations on how primary care providers can be better supported to expand access to MOUD in rural America.
PP - United States
PY - 2021
SN - 1547-0164; 0889-7077
SP - 1
EP - 7
EP - 
T1 - The who, the what, and the how: A description of strategies and lessons learned to expand access to medications for opioid use disorder in rural America
T2 - Substance abuse
TI - The who, the what, and the how: A description of strategies and lessons learned to expand access to medications for opioid use disorder in rural America
U1 - Education & Workforce; Healthcare Disparities; Opioids & Substance Use
U2 - 33689594
U3 - 10.1080/08897077.2021.1891492
VO - 1547-0164; 0889-7077
Y1 - 2021
Y2 - Mar 9
ER -